Payment overview · 2025
General Payments
$2,437.11
96 reported records · 23 companies
Healthcare provider profile · identity verified
Ray Hsiao, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HACIENDA HEIGHTS, CA · NPI 1164507869
Verified facts
What the public records show
CMS Open Payments records show Ray Hsiao, MD received $2,437.11 in general payments during 2025 across 96 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Kerendia, Linzess, Prolia, Rybelsus, Teriparatide, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 383 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 353 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Linzess by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rybelsus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $676.25 | 27.8% | 25 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $335.35 | 13.8% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $298.78 | 12.3% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $177.09 | 7.3% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $164.60 | 6.8% | 7 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $103.40 | 4.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $84.98 | 3.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $66.99 | 2.8% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $64.31 | 2.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $54.20 | 2.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $47.13 | 1.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $45.99 | 1.9% | 2 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $45.67 | 1.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $44.37 | 1.8% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $40.29 | 1.6% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $39.64 | 1.6% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $27.15 | 1.1% | 1 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $26.15 | 1.1% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $24.58 | 1.0% | 1 | 2025 |
| Zimmer Biomet Holdings, Inc. | Unresolved — no canonical attribution shown | $20.58 | 0.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.55 | 0.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.77 | 0.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.29 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,437.11 | 96 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $335.35 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $323.79 | 13 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $219.84 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $181.69 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $177.09 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $170.77 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $164.60 | 7 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $103.40 | 4 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $68.56 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $66.99 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $65.36 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $64.31 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $54.20 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $52.54 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $47.61 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $47.13 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $45.99 | 2 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $45.67 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $45.65 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $44.37 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $42.13 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $40.29 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $39.64 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $27.15 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Alvogen Inc | $26.15 | 1 | 2025 |
Source payment records
|
|||||
| VISCO-3 sodium hyaluronate Normalized: visco 3 sodium hyaluronate |
Device | Zimmer Biomet Holdings, Inc. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 383 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 353 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 45 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 141 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 96 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 38 | exact normalized | Medicare Part D |
| TERIPARATIDE teriparatide |
2025 | Teriparatide | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 142 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
141 | 50 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
96 | 65 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
383 | 99 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
45 | 29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
353 | 85 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
41 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
142 | 59 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
141 | 50 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
29 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1085 | 371 |
| Amlodipine Besylate | Amlodipine Besylate | 1015 | 316 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1009 | 282 |
| Ezetimibe | Ezetimibe | 873 | 289 |
| Losartan Potassium | Losartan Potassium | 858 | 256 |
| Metoprolol Succinate | Metoprolol Succinate | 398 | 116 |
| Farxiga | Dapagliflozin Propanediol | 383 | 99 |
| Famotidine | Famotidine | 357 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 354 | 93 |
| Jardiance | Empagliflozin | 353 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 342 | 117 |
| Metformin Hcl Er | Metformin Hcl | 339 | 104 |
| Alendronate Sodium | Alendronate Sodium | 287 | 103 |
| Januvia | Sitagliptin Phosphate | 287 | 54 |
| Azithromycin | Azithromycin | 285 | 217 |
| Metformin Hcl | Metformin Hcl | 276 | 75 |
| Vascepa | Icosapent Ethyl | 237 | 82 |
| Gabapentin | Gabapentin | 230 | 119 |
| Omeprazole | Omeprazole | 222 | 100 |
| Fluticasone Propionate | Fluticasone Propionate | 219 | 123 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 210 | 128 |
| Finasteride | Finasteride | 198 | 60 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 193 | 63 |
| Carvedilol | Carvedilol | 192 | 62 |
| Pioglitazone Hcl | Pioglitazone Hcl | 190 | 58 |
| Zolpidem Tartrate | Zolpidem Tartrate | 176 | 64 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 175 | 54 |
| Acarbose | Acarbose | 159 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 149 | 60 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 142 | 59 |
| Linzess | Linaclotide | 141 | 50 |
| Furosemide | Furosemide | 126 | 43 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 124 | 36 |
| Montelukast Sodium | Montelukast Sodium | 115 | 57 |
| Meloxicam | Meloxicam | 112 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 37 |
| Donepezil Hcl | Donepezil Hcl | 106 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 102 | 44 |
| Eliquis | Apixaban | 99 | 20 |
| Allopurinol | Allopurinol | 97 | 30 |
| Prolia | Denosumab | 96 | 65 |
| Simvastatin | Simvastatin | 95 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 91 | 74 |
| Mupirocin | Mupirocin | 90 | 56 |
| Azelastine Hcl | Azelastine Hcl | 89 | 43 |
| Glimepiride | Glimepiride | 84 | 26 |
| Mounjaro | Tirzepatide | 82 | 13 |
| Tradjenta | Linagliptin | 81 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 80 | 35 |
| Baclofen | Baclofen | 79 | 49 |
| Levofloxacin | Levofloxacin | 79 | 70 |
| Xarelto | Rivaroxaban | 78 | 23 |
| Valsartan | Valsartan | 77 | 24 |
| Lisinopril | Lisinopril | 74 | 18 |
| Nystatin | Nystatin | 74 | 43 |
| Potassium Chloride | Potassium Chloride | 74 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 69 | 41 |
| Trazodone Hcl | Trazodone Hcl | 56 | 33 |
| Atenolol | Atenolol | 54 | 17 |
| Restasis | Cyclosporine | 54 | 16 |
| Ammonium Lactate | Ammonium Lactate | 52 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 51 | 20 |
| Ciclopirox | Ciclopirox | 50 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 49 | 11 |
| Meclizine Hcl | Meclizine Hcl | 49 | 28 |
| Amoxicillin | Amoxicillin | 47 | 36 |
| Myrbetriq | Mirabegron | 47 | 13 |
| Memantine Hcl Er | Memantine Hcl | 46 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 46 | 27 |
| Sertraline Hcl | Sertraline Hcl | 46 | 13 |
| Kerendia | Finerenone | 45 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 22 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 41 | 27 |
| Folic Acid | Folic Acid | 40 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 13 |
| Fluocinonide | Fluocinonide | 38 | 19 |
| Rybelsus | Semaglutide | 38 | 12 |
| Nitroglycerin | Nitroglycerin | 37 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 35 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 35 | suppressed |
| Dutasteride | Dutasteride | 34 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | 11 |
| Hydrocortisone | Hydrocortisone | 33 | 24 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Teriparatide | Teriparatide | 31 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 30 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 12 |
| Entresto | Sacubitril/Valsartan | 29 | 14 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 22 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | 13 |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 26 | 23 |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | 16 |
| Telmisartan | Telmisartan | 26 | 11 |
| Cyclosporine | Cyclosporine | 25 | 14 |
| Lorazepam | Lorazepam | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 24 | 22 |
| Sucralfate | Sucralfate | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Methimazole | Methimazole | 23 | suppressed |
| Ztlido | Lidocaine | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | 12 |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Prednisone | Prednisone | 20 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | 11 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | 15 |
| Spironolactone | Spironolactone | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Entecavir | Entecavir | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 13 |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,437.11 · 96 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, LEQVIO, LINZESS, Leqembi, NEXLETOL, Ohtuvayre, Ozempic, PANCREAZE, PROLIA, Repatha, Rybelsus, TERIPARATIDE, TRELEGY ELLIPTA, Tymlos, VERQUVO, VISCO-3 sodium hyaluronate, XIFAXAN, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error